A Single Intra-articular Injection of Autologous Stromal Vascular Fraction for Moderate-to-Severe Knee Osteoarthritis: Results of a Multicentre Randomised Placebo-Controlled Trial With 12-Month Follow-up
The American Journal of Sports Medicine · 5 Nov 2026
† Impact is the editorial-priority score. All scores are out of 100. Clinical is how far this paper should move patient care if its methods hold up; it does not measure the size of a treatment benefit.
Why it matters
Cell-based injections for knee arthritis are widely marketed, so a sham-controlled trial showing a 12-month responder benefit (with a wide confidence interval and an unusual composite endpoint) is directly relevant to how you counsel patients asking about biologics.
The evidence
This multicentre trial randomised 114 adults with moderate-to-severe knee osteoarthritis to a single knee injection of 25 million of their own fat-derived stromal vascular fraction (SVF) cells or to a saline placebo injection; both groups underwent liposuction harvest. At 12 months, 51.8% of SVF patients versus 29% of placebo patients met the composite pain-and-function responder definition, a difference of 22.8 percentage points (95% CI 3.5 to 42.0). No serious device-related adverse events occurred.
Composite responder rate for direct treatment effect on pain (CII) and function (MCII) at 12 months: Risk difference 22.77 (95% CI 3.52 to 42.03; WOMAC). The interval favours the first group; the size of the benefit needs clinical interpretation.
Why this rigour score?
Sham-controlled RCTDesign starting point: 68.6
Raised the score
- Sham / placebo control+11.9
- Blinded outcome assessment+6.8
Lowered the score
- Underpowered−8.5
- Fragility index 1 (subspecialty median 2)−4.3
Methods at a glance
Recorded assessment- Outcome assessors blindedMet
- Allocation concealedMet
- Random sequence generatedNot reported
- Intention-to-treat analysisMet
- Adequate statistical powerUnderpowered
- Prospective registrationMet
Not reported does not mean not done. Checks have different weights; this is not a count of boxes ticked.
See the full score breakdown
- Study design starting point
- 68.6
- Concealed allocation
- +5.1
- Sham-controlled
- +6.8
- Placebo or sham control
- +5.1
- Blinded outcome assessment
- +6.8
- Intention-to-treat analysis
- +3.4
- 0% loss to follow-up
- +1.7
- Underpowered
- −8.5
- Prospectively registered
- +5.1
- No correction for multiple comparisons
- −3.4
- Fragility index 1 (subspecialty median 2)
- −4.3
- Final rigour score rounded
- 86 / 100
Study design sets the starting point and a ceiling of 100. Recorded methods then adjust the score. Points are shown to one decimal place; the final score uses unrounded values.
Checklist from the stored appraisal. “Not met” describes the recorded criterion; it does not always produce a deduction. This overview supports reading the full study.
How the clinical score was reached
The question: 7/9. Three judgements of how much it matters to patients, which decision it informs and how closely it fits their care.
Patient consequence: moderate (2/3). A patient-experienced outcome of real but smaller or shorter-lived importance: early pain or function, speed of recovery, return to sport or work, minor complications, satisfaction, or a validated score at a short time point.
Decision relevance: moderate (2/3). Bears on a real decision, but indirectly: an association or risk factor that informs counselling or surveillance, a subgroup or secondary analysis, one component of a pathway, or a comparison that leaves out a main alternative.
Applicability: moderate (3/3). A recognisable practice population, but with a notable restriction: narrow eligibility, a single expert surgeon or centre, or an unusual protocol that would need adapting. Applicability only subtracts for a real mismatch, so moderate counts in full.
What it found: Points one way (×0.86). A verdict without a usable interval, a clear result from a trial the paper itself calls underpowered, or a review whose certainty is low or unrated.
The design ceiling: 92. The most a sham-controlled rct can score here, however relevant its question and clear its answer.
Clinical = 92 × 7/9 × 0.86 = 62.
For journal club
1.For a patient with Kellgren-Lawrence grade 2 to 4 knee arthritis who has failed steroid and hyaluronic acid injections, how would you counsel them about SVF injection versus continued conservative care or arthroplasty, given that roughly half of treated patients responded?
2.Given that the benefit only appeared after about 4 months, how should expectations, follow-up timing, and the decision to proceed to knee replacement be managed after an SVF injection?
Original publication title
A Single Intra-articular Injection of Autologous Stromal Vascular Fraction for Moderate-to-Severe Knee Osteoarthritis: Results of a Multicenter Randomized Placebo-Controlled Trial With 12-Month Follow-up